Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2002

View Archived Issues

Orally bioavailable cathepsin inhibitors designed at Naeja

New growth hormone secretagogues claimed by Lilly

Vasopressin/oxytocin antagonists and their use in preterm labor, etc.

AstraZeneca presents novel antiarrhythmic agents

Schering describes histamine H3 antagonists for use in allergic rhinitis

Cytokine production inhibitors designed by Ortho-McNeil

Novel proton pump inhibitor prodrugs prepared and tested at Takeda

MacroGenics acquires Eliance, forms alliance with UT Southwestern

Abgenix and U3 Pharma collaborate to develop therapeutic antibodies for cancer

Phase II results announced for Ciprofloxacin GR

New antiepileptic agent with excellent safety profile identified at AWD

Novo Nordisk presents structurally novel DPP-IV inhibitor

New class of DNA-targeting antifungal agents in development at Genelabs

Approaches to design of clinically useful 5-HT6 antagonists discussed by GSK

AstraZeneca introduces new breast cancer therapy in first market

RWJ-67657 inhibits proinflammatory mediators in stimulated rheumatoid synovial fibroblasts

SMP-114 exerts beneficial effects on both inflammation and bone destruction in arthritis model

Phase IIb trial demonstrates clinical activity and good safety for CTLA4Ig in RA

Good safety profile reported for TZT-1027 in clinical trial in NSCLC

Imidacrine prevents cytokinesis and induces cell death after G2 arrest

Potential use of IP6 as a novel anticancer drug with antiangiogenic and cytotoxic properties

NicVAX enters phase I testing

Product R cleared for Israeli phase I study in leukemia and lymphoma

G17DT plus chemotherapy gives encouraging results in metastatic stomach cancer

Cipralex now available for prescription in three European markets

Complete response letter issued for Amevive in psoriasis

Vertex advances VX-702 into phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...